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Sunil S. Badve 13, Stefan Michiels14,15, William Fraser Symmans 16, Christos Sotiriou17, David L. Rimm 18,19, Stephen M. Hewitt20,
Carsten Denkert21,22, Sibylle Loibl23, Sherene Loi 24, John M. S. Bartlett25,26,27, Giancarlo Pruneri28,29, Deborah A. Dillon30,
Maggie C. U. Cheang31, Andrew Tutt32, Jacqueline A. Hall 33, Zuzana Kos34, Roberto Salgado24,35✉, Marleen Kok2,36,
Hugo M. Horlings 3,4 and International Immuno-Oncology Biomarker Working Group*
Stromal tumor-infiltrating lymphocytes (sTILs) are a potential predictive biomarker for immunotherapy response in metastatic
triple-negative breast cancer (TNBC). To incorporate sTILs into clinical trials and diagnostics, reliable assessment is essential. In this
review, we propose a new concept, namely the implementation of a risk-management framework that enables the use of sTILs as a
stratification factor in clinical trials. We present the design of a biomarker risk-mitigation workflow that can be applied to any
biomarker incorporation in clinical trials. We demonstrate the implementation of this concept using sTILs as an integral biomarker
in a single-center phase II immunotherapy trial for metastatic TNBC (TONIC trial, NCT02499367), using this workflow to mitigate risks
of suboptimal inclusion of sTILs in this specific trial. In this review, we demonstrate that a web-based scoring platform can mitigate
potential risk factors when including sTILs in clinical trials, and we argue that this framework can be applied for any future
biomarker-driven clinical trial setting.
npj Breast Cancer            (2020) 6:15 ; https://doi.org/10.1038/s41523-020-0155-1
INTRODUCTION
Clinical trials in cancer research are increasingly incorporating
biomarkers, for example, as an inclusion criterion or for stratifica-
tion of patients to control for confounding factors. Practical
challenges, such as interobserver variation in the assessment of
biomarkers during the execution of the trial, are often overlooked.
If not handled appropriately, these challenges can limit the
effectiveness and ability to complete the biomarker and drug
development process. According to Hall et al.1, the risks inherent
to biomarker integration can be divided into risks to patients,
operational risks, and direct risks to biomarker development. A
practical risk-management framework developed by a National
Cancer Institute (NCI), National Cancer Research Institute (NCRI),
and European Organization for Research and Treatment of Cancer
(EORTC) Working Group1 was proposed to manage the risks
inherent to biomarker integration into clinical trials.
Stromal tumor-infiltrating lymphocytes (sTILs) have been
strongly associated with prognosis in early-stage triple-negative
breast cancer (TNBC) and HER2-positive breast cancer. In addition,
sTILs are predictive for neo-adjuvant chemotherapy response in
early breast cancer2,3. Furthermore, sTILs correlate with outcome
after immune checkpoint blockade in metastatic TNBC4–6. The
readout of sTILs, however, can be challenging impeding its
effective use as a biomarker and its usage in the clinic7. The
International Immuno-Oncology Biomarker Working Group (here-
after called the TIL Working Group) has provided guidelines for
the scoring of sTILs in breast cancer8, and the St. Gallen Breast
Cancer Conference of 2019 endorsed sTILs being routinely
1Department of Research IT, The Netherlands Cancer Institute, Amsterdam, The Netherlands. 2Division of Tumor Biology and Immunology, The Netherlands Cancer Institute,
Amsterdam, The Netherlands. 3Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. 4Department of Pathology, The Netherlands
Cancer Institute, Amsterdam, The Netherlands. 5Department of Pathology, Ghent University Hospital, Ghent, Belgium. 6Department of Biometrics, The Netherlands Cancer
Institute, Amsterdam, The Netherlands. 7Department of Medicine, Perlmutter Cancer Center, New York University School of Medicine, New York, NY, USA. 8Department of
Radiation Oncology, Weill Cornell Medicine, New York, NY, USA. 9Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA. 10International
Breast Cancer Study Group Central Pathology Office, Department of Pathology and Laboratory Medicine, IEO European Institute of Oncology IRCCS, Milan, Italy. 11University of
Milan, Milan, Italy. 12Department of Pathology and Laboratory Medicine, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, BC, Canada.
13Department of Pathology and Laboratory Medicine, Indiana University Simon Cancer Center, Indianapolis, IN, USA. 14Service de Biostatistique et d’Epidémiologie, Gustave
Roussy, CESP, Université-Paris Sud, Université Paris-Saclay, Villejuif, France. 15CESP, Fac. de médecine - Univ. Paris-Sud, Fac. de médecine - UVSQ, INSERM, Université Paris-Saclay,
Villejuif, France. 16Department of Pathology, M.D. Anderson Cancer Center, Houston, TX, USA. 17Breast Cancer Translational Research Laboratory, Institut Jules Bordet, U-CRC,
Université Libre de Bruxelles, Brussels, Belgium. 18Department of Pathology, Yale School of Medicine, New Haven, CT, USA. 19Department of Medicine, Yale University School of
Medicine, New Haven, CT, USA. 20Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA. 21Institute of Pathology, Charité
Universitätsmedizin Berlin, Berlin, Germany. 22Institute of Pathology, Philipps-University Marburg, Marburg, Germany. 23German Breast Group, Neu-Isenburg, Germany. 24Division
of Research and Clinical Medicine, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia. 25Ontario Institute for Cancer Research, Toronto, ON,
Canada. 26IGMM, Edinburgh, UK. 27Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, UK. 28Department of Pathology and Laboratory Medicine, IRCCS
Fondazion - Instituto Nazionale Tumori, Milan, Italy. 29School of Medicine, University of Milan, Milan, Italy. 30Department of Pathology, Brigham and Women’s Hospital, Harvard
Medical School, Boston, MA, USA. 31Clinical Trials and Statistics Unit, The Institute of Cancer Research, Surrey, UK. 32Breast Cancer Now Toby Robins Research Centre, The Institute
of Cancer Research, London, UK. 33Research and Development, Vivactiv Ltd, Chesham, Buckinghamshire, UK. 34Department of Pathology and Laboratory Medicine, University of
Ottawa, Ottawa, ON, Canada. 35Department of Pathology, GZA-ZNA Ziekenhuizen, Antwerp, Belgium. 36Department of Medical Oncology, The Netherlands Cancer Institute,
Amsterdam, The Netherlands. *A list of authors and their affiliations appears at the end of the paper. ✉email: roberto@salgado.be
www.nature.com/npjbcancer
Published in partnership with the Breast Cancer Research Foundation
1
2
3
4
5
6
7
8
9
0
()
:,;
characterized in TNBC and reported according to these
guidelines8.
RISKS ASSOCIATED WITH INTEGRATION OF BIOMARKERS IN
CLINICAL TRIALS
In contemporary clinical research there is an increasing trend
toward the use of biomarker results obtained in daily practice to
select patients for inclusion in clinical trials. Although biomarker
research is more and more prominent in clinical trials, most
biomarkers will not make into the clinic9. Therefore, continuous
monitoring of the predefined risks and the solutions can improve
the quality of the biomarker, which can be applied in a clinical trial
setting, as well as in daily practice. The recommendations of the
TIL Working Group8,10 for appropriate scoring, and the risk-
management framework of the NCI, NCRI, and EORTC Working
Groups1 will help to effectively and efficiently improve the
incorporation of biomarkers in clinical trials in first instance.
Several risks are associated with biomarker development and
integration of biomarkers in clinical trials. Roughly, risks can be
divided into three categories: risks to patient safety, operational
risks, and risks to biomarker development. Not all risks are
applicable to all clinical trials and upon designing a biomarker-
incorporating clinical trial, risks should be defined and mitigation
approaches formulated. It is highly recommended that during a
clinical trial, risks are not only pre-identified but are also
continuously monitored to prevent stagnation in biomarker
development1. For example, incorporating biomarkers in a large
multi-center international clinical trial involves different risks than
a small single-center trial. In the first case, there might be different
legislation regarding data confidentiality, and inter-laboratory
variability can be an issue. When incorporating a biomarker as
inclusion criterion or stratification factor in clinical trials, rapid
turnaround times are needed and the highest level of quality is
necessary for correct interpretation of the results. In the next steps
of biomarker development, high-quality results are needed to
ensure implementation in daily clinical practice.
USE OF DIGITAL PATHOLOGY IN CLINICAL TRIALS AND
DEVELOPMENT OF A NOVEL WEB APPLICATION
In larger trials, usually phase II–III, central pathology review (CPR)
plays an important role in the reliable assessment of biomarker
scoring. However, logistical issues, such as the sending of tumor
blocks or slides, can be time consuming, costly for the pathology
laboratory, and error prone with significant consequences for
patient inclusion if the wrong material is sent to the central lab.
Digital sharing of histology slides and patient data simplifies
logistics for CPR11. Besides digital sharing and scoring of slides,
digital image analysis and machine learning approaches are
emerging in clinical research12,13. The use of digital pathology or
digital evaluation of histology slides most prominently mitigates
risks associated with operational processes. It can reduce the
number of missing samples, since the sharing of material is
simplified; it enables rapid turnaround times; reduces manual
errors; and can streamline local versus central assessment of
biomarker.
For clinicians and researchers to use digital pathology,
applications and websites should be user-friendly and intuitive.
As an example, a web-based tool called Slide Score (www.
slidescore.com) was developed as a cross-platform web applica-
tion to facilitate the scoring of whole slide images and tissue
microarray (TMA) cores. Application programming interface (API)
was implemented that allowed programmatic administration of
studies, uploading slides, fetching results, and retrieving pixel data
for regions of images. This API enabled automating creation of
new studies from internal database system for managing
biobanking workflows. Additionally, a plugin was developed for
QuPath14—open-source image analysis software—which uses this
API to run image analysis algorithms on slides stored on the Slide
Score platform avoiding the need to download the slides. This
web-based platform was used in high-impact projects6,15, for
example, for the digital scoring of biomarkers in the first stage of
the TONIC trial6, and the estimation of the immune infiltrate of
tumors of melanoma patients used for single-cell sequencing15.
Furthermore, the web-based platform is currently used for several
other types of research, such as interrater variability studies,
retrospective TMA, and whole slide scoring and prospective
biomarker scoring.
DESIGN OF A WORKFLOW TO MITIGATE RISKS ASSOCIATED
WITH BIOMARKER DEVELOPMENT: AN EXAMPLE
We identified seven distinct risks with the risk-management
framework published by Hall et al.1 as possibly interfering with the
quality and integration of prospective sTILs scores in a clinical trial,
and designed our workflow accordingly (Table 1). These risks are
specific for this trial, but some of them are applicable also to other
trials. They span all three categories mentioned above1 and
included (1) poor-quality biopsies, (2) possible loss of data
confidentiality, (3) interrater variability, (4) poor sample quality,
(5) poor scoring quality, (6) delay in patient registration, and (7)
manual errors (Table 1). We then defined solutions to mitigate
these risks and integrated these solutions in a workflow that can
be applied across clinical trials and across biomarkers (Fig. 1). The
workflow can be modified according to local guidelines, research
questions, and clinical trial designs. We used the following
workflow to obtain timely and reliable sTILs scores (summary in
Supplementary Fig. 1).
After obtaining informed consent of a patient, three biopsies of
one metastatic lesion (lymph node, skin, liver, or other) were
obtained in this trial. Previous research has shown that three 14 G
core needle biopsies should be sufficient for accurate breast
cancer diagnosis16. A hematoxylin and eosin (H&E)-stained slide of
one biopsy was then evaluated, to ensure that the biopsy
contained enough tumor cells (more than 100 cells) for further
analysis (risk 1). Next, a high-resolution digital scan was obtained
and automatically pseudonymized with study-specific identifiers
(risk 2) before uploading to Slide Score. Display of the original
labels was masked to ensure confidentiality of all data within Slide
Score (Supplementary Fig. 2b). Pathologists and administrators
had to login with their username and password to access the
slides and were able to add a two-factor authentication
application. Four well-trained breast pathologists, based in three
different institutes and in two different countries, were notified via
email to score each slide using existing sTIL scoring guidelines of
the TIL Working Group8,10 to reduce interrater variability (risk 3).
sTILs are scored as the percentage of lymphocytes in the total
stromal area (in close proximity of the tumor cells). Interrater
variability can lead to bias in the results, when assessment of a
biomarker is skewed towards either the lower or higher ranges.
When there was a disagreement (using a 5% cut-off) a
concordance-score was agreed upon (Supplementary Fig. 1).
Low-quality, inaccurate collection or processing of samples can
result in low sample availability and introduce batch effects or bias
in the results (risk 4) and lead to non-consistent scores (risk 5).
High quality of samples was ensured by standardization of our
workflow in which all steps were performed in the same manner
for every biopsy (Supplementary Fig. 1). Oversight of the entire
workflow by one person, referred to as the central manager, is
essential for timely identification of technical errors. The central
manager tracked the timing of the biopsies, notified the
pathologists immediately after the scan was uploaded and sent
reminders if necessary, kept track of the scores and timing, and
noted the score in the patient record for trial office notification.
We predefined acceptable timeframes for obtaining the scores of
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the reviewers and tracked these during the study progress (risk 6;
Supplementary Fig. 1). Pathologists were notified via email the
next working day when the slide was not scored yet to minimize
the waiting period to start treatment (risk 6). Finally, using Slide
Score, we reduced the risks of typos and other manual errors by
collecting all slides within one online study group (collection of
slides) and a customized scoring form was built to standardize
scores and obtain structured data (risk 7).
IMPLEMENTATION OF WORKFLOW IN THE TONIC TRIAL
The TONIC trial (NCT02499367)6 is a phase II, non-comparative
randomized multi-cohort single-center trial (full title: Adaptive
phase II randomized non-comparative Trial Of Nivolumab after
Induction treatment in TNBC patients), designed to assess the
efficacy of induction of an anti-cancer immune response by low-
dose chemotherapy or irradiation to increase response to anti-PD-
1 in patients with metastatic TNBC. In the first part of the trial6,
patients with metastatic TNBC were randomized to nivolumab (1)
without induction or two-week low-dose induction, with (2)
irradiation (3 × 8 Gy), (3) cyclophosphamide, (4) cisplatin, or (5)
doxorubicin, all followed by nivolumab (anti-PD-1; 3 mg/kg). Based
on a Simon’s two-stage design17 and prespecified pick-the-winner
criteria, only the doxorubicin cohort was allowed to continue in
the second part of the trial6. In the second part of the TONIC trial,
patients were randomized between anti-PD-1 monotherapy
(control group) and two cycles of low-dose doxorubicin (15 mg
flat dose, weekly), followed by anti-PD-1 (Supplementary Fig. 2a).
Randomization was stratified for sTILs. Stratification is done by
dividing patients in two categories, namely sTILhigh (equal or
exceeding 5%) and sTILlow (lower than 5%). The cut-off was
determined based on data obtained in the first part of the TONIC
trial, in which we observed that sTILs were predictive of response
to anti-PD-1, both continuous and when a cut-off of 5% was used6.
These data confirmed the predictive value of sTILs of at least 5% in
another trial, which tested the efficacy of anti-PD-1 in patients
with metastatic TNBC4. The full protocol, including four amend-
ments, and the informed consent form were approved by the
medical-ethical committee of The Netherlands Cancer Institute. All
patients provided written informed consent before enrollment.
The trial was registered on 17 August 2015. The 47 patients of the
second part of the trial were randomized between March 2018T
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Web-based 
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Center n: Scan
Center 1: Scan
1. Upload
1. Up
load
Central Manager
3. 
No
tify
Pathologists
Trial Office
5. Send results
4. Score
2. Check
quality
Fig. 1 Organization of a workflow for reliable and timely
biomarker scoring in a general single-center or multi-center trial.
Personnel at individual centers scan the slides after processing by
the local pathology department. Digital slides are uploaded to a
central web-based repository, such as Slide Score. A study-specific
identifier is assigned to each sample. The central manager is notified
by the system when new slides are available and requests
pathologists to review it. When a consensus score is obtained, the
trial office is notified for randomization of the patient.
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and July 2019. Full eligibility criteria and trial procedures have
been described previously6.
In the second part of the TONIC trial, we could implement our
workflow with a focus on accurate and reproducible sTIL scores
within a reasonable timeframe after a biopsy was taken (72 h). For
all 47 patients included in the trial, reliable sTIL scores were
obtained with 45 biopsies scored within the 72-h timeframe
(Supplementary Fig. 3). During the course of the study, the server
of Slide Score was available 99.9% of the time. Five biopsies had to
be re-evaluated due to a discrepancy in the categorical scores,
when not all pathologists agreed on the appropriate category of
the sTIL score (lower than 5% versus higher or equal to 5%). In
three of these cases the score of one pathologist was higher (5 or
10%) than the score of the other two or three pathologists (0–3%).
The average sTIL score was obtained and the pathologist causing
the disagreement was notified. In the fourth and fifth case, two
pathologists scored 5 and 10%, whereas the other pathologists
scored 1%. All four pathologists were notified of the disagreement
and a consensus score of 5% was obtained. We observed an
intraclass correlation coefficient of 0.94 (95% confidence interval
(CI): 0.91–0.97) for sTILs as a continuous variable. Interrater
agreement for the categorical variable used in the stratification
(sTILs <5% or ≥5%) was 0.86 (multirater Fleiss’ κ18; 95% CI: 0.73–1;
Supplementary Fig. 2c). In the anti-PD-1 monotherapy cohort, we
observed that 13 out of 23 patients (56.5 %) had sTILs below 5%,
as compared to 15 out of 24 patients in the doxorubicin cohort
(62.5 %; Fisher’s exact test p value 0.77). The distribution of the
sTIL scores is depicted in Supplementary Fig. 2d. These data
indicate effective stratification based on the cut-off of 5%, but a
slightly uneven distribution in the higher ranges of sTIL scores
(10% or higher) inherent to the use of our cut-off. We observed a
median time from biopsy until the scanning of the H&E slide of
30 h (range 24–98 h) and a median time from the biopsy until at
least three scores were obtained of 43 h (range 27–106 h). In total,
the median time from biopsy until registration in the patient
records was 49 h (range 41–106 h; Supplementary Fig. 2e), with
96% of biopsies scored within 72 h. Two biopsies were not scored
within the 72-h time limit, due to additional processing of one
sample and one delay in registration time due to the absence of
the central manager (Supplementary Figs 1 and 3).
ADVANTAGES AND LIMITATIONS OF A WEB-BASED RISK-
MITIGATION WORKFLOW
Our proposed solutions involved standardization of our workflow,
obtaining digital images and the use of a web-based tool such as
Slide Score for the managing and scoring of digital images.
Anticipating the incorporation of digital images in routine
diagnostics, our workflow shows that it is feasible for a pathologist
to score digital images with high reliability. Moreover, a web-
based tool can facilitate the process of coordinated uploading of
digital images, pseudonymizing slides, and regulate access to
studies and proper data management. Web-based platforms are
therefore of high interest in biomarker research and can help with
automation that can be transferred to clinical practice in the
future.
In this study, we obtained sTIL scores within 72 h after a biopsy
was taken, which is a reasonable timeframe for clinicians to start
randomization of patients to treatment arms in a clinical trial. We
observed an excellent interrater agreement score between our
panel of four expert pathologists. In an accompanying paper7 we
demonstrate using data from three RING studies of the TIL
Working Group that the concordance achieved using a risk-
management approach as detailed in this study is substantially
higher than observed outside this risk-management perspective
as observed in the three RING studies and in other published
studies19,20. However, our sample size is small and the four
pathologists in the current study were trained and experienced in
the scoring of sTILs in breast cancer. Also, the biopsies used in this
study were checked for containing sufficient tumor cells (≥100
cells) before the slide was scored for sTILs, which could have
further improved our results. In the future, it is to be expected that
computational workflows will further improve the scoring of
sTILs13. Although we obtained reliable and timely results in 96% of
cases, the presence of a central manager is crucial. In one case
there was a delay in registration time due to the absence of the
central manager. The manual intervention of quality checks,
processing of the slides, and data cannot be circumvented in our
workflow.
Stratification in this study was performed using sTILs as a binary
variable (lower than 5% versus higher or equal to 5%).
Consequently, we observed an uneven distribution in continuous
sTILs scores between the cohorts (Supplementary Fig. 2d). This
was mainly due to more patients with sTILs scores above 10% in
the anti-PD-1 monotherapy cohort. Inherent to the use of a binary
cut-off for stratification, the median of the continuous measure-
ment might still differ between cohorts. Alternatively, multiple
categories for the same variable can be used in stratification.
However, this approach generates more strata, with lower number
of patients in each stratum, possibly leading to an imbalance in
distribution21,22. Moreover, at the time of writing of this paper no
cut-offs for sTILs are established and/or properly validated for
predictive purposes.
During the trial, we continuously monitored whether our
strategy was still feasible within the set timeframe by means of
regular evaluation by the pathologists and the study coordinators.
This led to rapid adjustment of the workflow if needed, ensuring
the quality of the sTIL scores. For example, pathologists could
easily login remotely and score a digital H&E outside the hospital
ensuring that sTILs were still scored within 72 h after biopsy.
Ongoing evaluation during the clinical trial is of critical importance
for risk mitigation in biomarker research1.
FUTURE APPLICATIONS OF THE WORKFLOW
Our strategy can serve as a template for risk management and
mitigation of all identified risks in future clinical trials incorporat-
ing biomarkers for inclusion, enrichment, or stratification. By no
means will risks identified in this study be similar for all clinical
trials. Each trial will have its own risks that need to be mitigated,
although there will be similarities between the risks across clinical
trials. Defining the risks that come with biomarker development
will help tested biomarkers eventually make their way to the clinic.
However, one may even argue that a similar risk-management
strategy can be applied in daily practice. In the BELLINI trial
(NCT03815890), two cycles of neo-adjuvant anti-PD-1 are adminis-
tered in patients with early-stage TNBC or luminal B breast cancer.
All patients are required to have at least 5% sTILs in the
pretreatment biopsy and patients are thereafter stratified in three
sTIL categories. Our workflow will be used to ensure timely and
reliable sTIL scores for the right patient selection. By using our
workflow, scoring of sTILs is highly standardized, allowing also
smaller centers with less extensive experience in sTILs scoring to
participate in a clinical trial.
CONCLUSIONS
In contemporary clinical research there is an increasing trend
toward the use of biomarker results obtained in daily practice to
select patients for inclusion in clinical trials. Therefore, continuous
monitoring of the predefined risks and the solutions can improve
the quality of the biomarker, as can be applied in a clinical trial
setting, as well as in daily practice. The recommendations of the
TIL Working Group8,10 for appropriate scoring, the risk-
management framework of the NCI, NCRI, and EORTC Working
Groups1, as well as our proposed strategies to reduce risks will
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help to effectively and efficiently improve the incorporation of
biomarkers in clinical trials in first instance, herewith illustrated
using sTILs as a paradigm of this development.
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